Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Austin, TX, USA, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “T-Cell Engagers Market Size, Trends and Insights By Product Type (BiTEs...
-
EOM Pharmaceutical Holdings Report Promising Preclinical Results and Provides an Update on EOM613 and EOM147
-
Oxford, UK and Boston, MA – January 6, 2026 – Sitryx Therapeutics (“Sitryx” or “the Company”), a clinical-stage biopharmaceutical company developing novel oral therapies to restore immune balance in...
-
CLE is the second indication InnoCare is developing for ICP-488, and enrollment for the phase III study of ICP-488 for psoriasis is nearing completion.
-
New York, Dec. 12, 2025 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) recognizes the U.S. Food and Drug Administration (FDA) approval of Amgen’s UPLIZNA® (inebilizumab-cdon) for the...
-
InnoCare's pipeline under development now covers ten major autoimmune diseases, with a particular focus on dermatological conditions.
-
Oxford, UK and Boston, MA – November 13, 2025 – Sitryx Therapeutics (“the Company”), a clinical-stage biopharmaceutical company developing novel oral therapies to restore immune balance in autoimmune...
-
$32 million new equity injection adds to previously announced $59 millionNew investors Tencent and BGF joined by all existing major shareholdersFunds will advance pipeline of novel TCR-CD3...
-
Preclinical data highlight that PKM2 modulation inhibits several important mechanisms underlying atopic dermatitis pathologySYX-5219 is a first-in-class oral PKM2 modulator designed to drive...
-
New York, Nov. 03, 2025 (GLOBE NEWSWIRE) -- New York, Monday, November 3, 2025 – The Muscular Dystrophy Association (MDA) marks another milestone today in our legacy of progress with the FDA...